|Table of Contents|

Research status of drug sensitivity test in vitro in the treatment of lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2926-2931
Research Field:
Publishing date:

Info

Title:
Research status of drug sensitivity test in vitro in the treatment of lung cancer
Author(s):
WANG Yun1; LIU Feiyang2; ZHANG Liwei1
1.Hefei Cancer Hospital,Chinese Academy of Sciences,Anhui Hefei 230031，China;2.Institute of Health and Medical Technology,Hefei Institutes of Physical Science,Chinese Academy of Sciences,Anhui Hefei 230031，China.
Keywords:
in vitro drug sensitivity test; lung cancer; organoid; PTC; microfluidic chip; HDS; organoids-on-chips; research progress
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.15.031
Abstract:
Lung cancer is a major "killer" that threatens human health,and the current treatment methods cannot meet the clinical needs.Chemotherapy is the most commonly used method for non-surgical treatment of lung cancer.However,due to substantial genetic and phenotypic heterogeneity across individuals,cases of tumor multidrug resistance and treatment failure happen commonly.In order to avoid the blindness of chemotherapy and improve the efficiency of chemotherapy,personalised medicine based on in vitro drug sensitivity assay have emerged.A series of clinical trials have been carried out confirming that in vitro drug sensitivity testing has important guiding significance for individualized treatment of cancer.In this paper,several of the most commonly used anti-cancer drug sensitivity testing methods are reviewed,including the emerging methods based on organoids,PTCs,microfluidic chips,HDS and organoid chips.This review is aimed at evaluating the latest research progress of in vitro drug sensitivity test in lung cancer.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］LI Y,MA C,SHI X,et al.Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer［J］.Oncol Rep,2014,32(4):1703-1708.
［3］ALEXANDER M,KIM SY,CHENG H.Update 2020:Management of non-small cell lung cancer［J］.Lung,2020,198(6):897-907.
［4］VINAYANUWATTIKUN C,PRAKHONGCHEEP O,TUNGSUKRUTHAI S,et al.Feasibility technique of low-passage in vitro drug sensitivity testing of malignant pleural effusion from advanced-stage non-small cell lung cancer for prediction of clinical outcome［J］.Anticancer Res,2019,39(12):6981-6988.
［5］PAPP E,STEIB A,ABDEIWAHAB EM,et al.Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas［J］.BMJ Open Respir Res,2020,7(1):e000505.
［6］李恒善,云耀峰,梁润,等.应用MTT法对恶性肿瘤原代细胞培养进行规范化体外药敏试验的研究［J］.中国实用医药,2020,15(3):197-198. LI HS,YUN YF,LIANG R,et al.Study on standardized in vitro drug sensitivity test of malignant tumor primary cell culture by MTT method［J］.China Practical Medicine,2020，15(3):197-198.
［7］GLAYSHER S,CREE IA.Cell sensitivity assays:the ATP-based tumor chemosensitivity assay［J］.Methods Mol Biol,2011,731:247-257.
［8］UNTCH M,DITSCH N,LANGER E,et al.Chemosensitivity testing in gynecologic oncology-dream or reality［J］.Recent Results Cancer Res,2003,161:146-158.
［9］HIGASHIYAMA M,ODA K,OKAMI J,et al.Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients［J］.Lung Cancer,2010,68(3):472-477.
［10］YOSHIMASU T,OURA S,HIRAI I,et al.Data acquisition for the histoculture drug response assay in lung cancer［J］.J Thorac Cardiovasc Surg,2007,133(2):303-308.
［11］HOFFMAN RM.Clinical correlation of the histoculture drug response assay for head and neck cancer［J］.Methods Mol Biol,2018,1760:83-92.
［12］CLEVERS H.Modeling development and disease with organoids［J］.Cell,2016,165(7):1586-1597.
［13］SATO T,VRIES RG,SNIPPERT HJ,et al.Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche［J］.Nature,2009,459(7244):262-265.
［14］KIM M,MUN H,SUNG CO,et al.Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening［J］.Nat Commun,2019,10(1):3991.
［15］VLACHOGIANNIS G,HEDAYAT S,VATSIOU A,et al.Patient-derived organoids model treatment response of metastatic gastrointestinal cancers［J］.Science,2018,359(6378):920-926.
［16］GUO QR,ZHANG LL,LIU JF,et al.Multifunctional microfluidic chip for cancer diagnosis and treatment［J］.Nanotheranostics,2021,5(1):73-89.
［17］YU F,CHOUDHURY D.Microfluidic bioprinting for organ-on-a-chip models［J］.Drug Discov Today,2019,24(6):1248-1257.
［18］YIN S,XI R,WU A,et al.Patient-derived tumor-like cell clusters for drug testing in cancer therapy［J］.Sci Transl Med,2020,12(549):eaaz1723.
［19］刘飞扬,黄瑞,任涛,等.肿瘤精准用药治疗的技术体系［J］.高科技与产业化,2016,242(7):50-52. LIU FY,HUANG R,REN T,et al.The technical system of tumor precision medication treatment［J］.High-tech and Industrialization,2016,242(7):50-52.
［20］ZHENG F,XIAO Y,LIU H,et al.Patient-specific organoid and organ-on-a-chip:3D cell-culture meets 3D printing and numerical simulation［J］.Adv Biol（Weinh),2021,5(6):e2000024.
［21］PARK SE,GEORGESCU A,HUH D.Organoids-on-a-chip［J］.Science,2019,364(6444):960-965.
［22］AU SH,CHAMBERLAIN MD,MAHESH S,et al.Hepatic organoids for microfluidic drug screening［J］.Lab Chip,2014,14(17):3290-3299.
［23］WANG Y,JIANG T,QIN Z,et al.HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib［J］.Ann Oncol,2019,30(3):447-455.
［24］JIA Z,WANG Y,CAO L,et al.First-line treatment selection with organoids of an EGFRm+TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up［J］.J Thorac Dis,2020,12(7):3764-3773.
［25］VLACHOGIANNIS G,HEDAYAT S,VATSIOU A,et al.Patient-derived organoids model treatment response of metastatic gastrointestinal cancers［J］.Science,2018,359(6378):920-926.
［26］OOFT SN,WEEBER F,DIJKSTRA KK,et al.Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients［J］.Sci Transl Med,2019,11(513):eaay2574.
［27］WEEBER F,OOFT SN,DIJKSTRA KK,et al.Tumor organoids as a pre-clinical cancer model for drug discovery［J］.Cell Chem Biol,2017,24(9):1092-1100.
［28］CRYSTAL AS,SHAW AT,SEQUIST LV,et al.Patient-derived models of acquired resistance can identify effective drug combinations for cancer［J］.Science,2014,346(6216):1480-1486.
［29］王丹,潘跃银.高通量体外药敏检测技术在晚期肺癌伴恶性胸水中的临床研究［J］.世界最新医学信息文摘,2018,18(58):6-7. WANG D,PAN YY.Clinical study of high-throughput in vitro drug sensitivity detection technology in advanced lung cancer with malignant pleural effusion［J］.World Latest Medicine Information,2018,18(58):6-7.
［30］LIU X,WANG W,YIN Y,et al.A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer［J］.Invest New Drugs,2019,37(6):1166-1176.
［31］XU Z,GAO Y,HAO Y,et al.Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer［J］.Biomaterials,2013,34(16):4109-4117.
［32］JUNG DJ,SHIN TH,KIM M,et al.A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity［J］.Lab Chip,2019,19(17):2854-2865.
［33］HU Y,SUI X,SONG F,et al.Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week［J］.Nat Commun,2021,12(1):2581.

Memo

Memo:
安徽省卫生健康委员会科学研究项目（编号：AHWJ2021b087）
Last Update: 2023-06-30